FLNA, a disulfidptosis-related gene, modulates tumor immunity and progression in colorectal cancer
Open Access
- 26 July 2025
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 30 (1) , 1-22
Abstract
Disulfidptosis represents a novel type of regulated cell death induced by excessively high intracellular levels of cystine. Targeting disulfide imbalance is considered a promising treatment approach for colorectal cancer (CRC). However, the involvement of disulfidptosis in CRC immunotherapy is undefined. Unsupervised clustering was applied to The Cancer Genome Atlas (TCGA) datasets to classify disulfidptosis-related phenotypes. The tumor microenvironment (TME) was characterized using diverse bioinformatics algorithms, including gene set variation analysis (GSVA) for pathway enrichment analysis and CIBERSORT for immune cell profiling. A disulfidptosis-related gene (DRG) signature was generated for stratifying CRC cases, and univariate Cox regression was utilized for identifying prognostic DRGs. Filamin A (FLNA) was pinpointed as a pivotal regulator of disulfidptosis, and its functional impacts on tumor progression and immunotherapy response were further investigated. Two different groups were determined on the basis of the built disulfidptosis-related signature (DRS), showing distinct clinical outcomes, as well as different pathway activation, drug sensitivity, and immune infiltration patterns. The high-DRS subgroup correlated with poorer prognosis, elevated immunosuppressive cell activity, and reduced cytotoxic immune cell infiltration. FLNA emerged as a critical mediator of disulfidptosis in CRC, with its knockdown suppressing tumor cell migration and invasion in vitro. The FLNA inhibitor PTI-125 attenuated tumor growth and epithelial–mesenchymal transition (EMT), while FLNA depletion reversed glucose-driven metastasis. Notably, combined glucose transporter 1 (GLUT1) inhibition and anti-programmed cell death protein 1 (PD-1) therapy enhanced CD8+ T cell recruitment and suppressed EMT. This study elucidates the interplay between disulfidptosis and the CRC immune landscape, highlighting FLNA as a therapeutic target. These findings suggest that modulating disulfidptosis in conjunction with immunotherapy may offer a novel treatment paradigm for CRC.Keywords
Funding Information
- National Natural Science Foundation of China (82104749, 82274250)
- National Natural Science Foundation of China (82305345)
- Beijing Natural Science Foundation (5212003)
- Beijing KeChuang Medical Development Foundation (KC2021-JX-0186-127)
This publication has 76 references indexed in Scilit:
- Is the voltage-gated sodium channel β3 subunit (SCN3B) a biomarker for glioma?Functional & Integrative Genomics, 2024
- hsa-miR-CHA2, a novel microRNA, exhibits anticancer effects by suppressing cyclin E1 in human non-small cell lung cancer cellsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer developmentBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023
- Small extracellular vesicles-mediated cellular interactions between tumor cells and tumor-associated macrophages: Implication for immunotherapyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023
- Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023
- Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instabilityAnnals of Oncology, 2023
- EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data2020
- Profiling Tumor Infiltrating Immune Cells with CIBERSORT2018
- Filamin A expression correlates with proliferation and invasive properties of human metastatic melanoma tumors: implications for survival in patientsJournal of Cancer Research and Clinical Oncology, 2014
- Filamin a mediates HGF/c‐MET signaling in tumor cell migrationInternational Journal of Cancer, 2010